SheMed Raises $50 Million to Accelerate UK Women’s Weight Loss Revolution

We are thrilled to announce a monumental milestone for the SheMed community: we have successfully raised $50 million in Series A funding, officially valuing SheMed at $1 billion and cementing our status as a Unicorn company.

This landmark investment is more than just capital; it is a powerful validation of our mission and the extraordinary, unmet demand for truly personalised, women-focused healthcare.

Validation of Our Mission: Personalised Care

In less than a year since our founding in April 2024, SheMed has grown into the UK’s fastest-growing GLP-1 programme, empowering over 60,000 members with a sustainable path to better health. This journey has been driven by the need to replace 'one-size-fits-all' treatments with clinically precise, compassionate, and accessible care.

As our Co-Founder and CEO, Olivia Ferro, explains:

“Achieving unicorn status validates the scale of the unmet needs for world-class GLP-1 care. Having been a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands, and empowers.”

Accelerating Our UK Expansion and Innovation

This new funding will be strategically invested to significantly expand our operations across the United Kingdom and enhance the quality of care our members receive.

The investment will be used to:

• Scale Our Teams: Grow our medical, clinical, and technology teams to ensure every member receives best-in-class support.
• Strengthen Clinical Infrastructure: Enhance our capabilities and platform to maintain clinical excellence and safety.
• Advance Research: Support new research initiatives, including the upcoming publication of the first-ever female-focused GLP-1 clinical study. These findings will provide critical insights into how these medications affect women's unique hormonal and metabolic responses, helping us refine future treatment pathways for all women.

Co-Founder and President, Chloe Ferro, emphasises the market demand:

"The demand for SheMed's services has been extraordinary. Women are seeking care that recognises their individuality, their biology, and their experiences. It's why women continue to turn to SheMed for a tailored, more supportive path to healthcare.”

The SheMed Difference: Built By Women, For Women

SheMed is redefining weight management and women’s metabolic health by integrating advanced medical oversight, data-driven insights, and continuous support through an all-in-one digital platform.

Our dedication to clinical precision is paramount. Unlike standard telehealth providers, SheMed requires a comprehensive at-home blood test for eligibility and tracking. This crucial step ensures that treatment plans are safe and tailored to your specific biology, providing you with a foundation for lasting health results.

This $50 million funding round marks the beginning of our next chapter—a chapter dedicated to scaling our impact and delivering truly world-class, personalised healthcare to every woman in the UK.

Thank you to our members and our partners for believing in the SheMed mission. We are just getting started.